Asterias Biotherapeutics (AST) Announces FDA Clearance to Enroll C-4 Patients in SCiStar Study

July 10, 2017 7:04 AM EDT Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login